Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Clinicaltrials gov surfactant rsv bronchiolitis poractant alfa trial nct?

What NCT trial on ClinicalTrials.gov matches “poractant alfa” for RSV bronchiolitis?

I can’t determine the exact NCT (National Clinical Trial) number from the information provided. “Poractant alfa” is a surfactant used in neonates, and “RSV bronchiolitis” is typically studied in infants, so there may be either a direct “poractant alfa + RSV bronchiolitis” study or a different wording on ClinicalTrials.gov (for example, “surfactant” rather than “poractant alfa,” or “RSV-associated” bronchiolitis rather than “RSV bronchiolitis”).

If you paste the ClinicalTrials.gov link or the exact trial title text you’re looking at, I can confirm the NCT number and summarize the study details.

Quick way to find the exact NCT on ClinicalTrials.gov (what to search)

On ClinicalTrials.gov, use these targeted searches:
- “poractant alfa”
- “poractant” AND “bronchiolitis”
- “surfactant” AND “RSV”
- “RSV-associated bronchiolitis” AND “surfactant”

Then open the result pages and capture the “NCT” identifier shown at the top (it will look like NCT########).

What study details matter once you find the NCT?

When you open the correct NCT page, look for:
- Population: infant age range and whether enrollment is limited to RSV-positive cases
- Intervention: dosing and delivery route of poractant alfa (or a surfactant comparator)
- Design: randomized vs open-label, placebo/control arm, blinding
- Primary endpoint: usually a clinical severity score, oxygen requirement duration, or time to clinical improvement
- Status and dates: recruiting/active/not recruiting and the study start/completion dates

Why the “poractant alfa + RSV bronchiolitis” match might be tricky

ClinicalTrials.gov entries sometimes use different names:
- The drug may be listed generically as “poractant alfa” (spelling variations exist)
- The condition may be described as “bronchiolitis” without explicitly stating “RSV,” with RSV status captured by inclusion criteria
- Some studies use “exogenous surfactant” or “surfactant therapy” as the intervention description rather than brand drug names

If you share one detail, I can pinpoint it fast

Reply with either:
- the ClinicalTrials.gov URL you found, or
- the trial title (even partial), or
- any phrase from the trial’s “Condition” or “Intervention” fields

…and I’ll give you the exact NCT number and a concise trial summary (design, endpoints, and results/status).

Sources

No sources were provided in your message, and I don’t have enough information to reliably identify the specific ClinicalTrials.gov record.



Other Questions About Poractant :

clinicaltrials.gov poractant alfa bronchiolitis trial nct clinicaltrials.gov surfactant rsv bronchiolitis poractant alfa trial nct clinicaltrials.gov poractant alfa bronchiolitis nct poractant alfa (curosurf) clinicaltrials.gov poractant alfa bronchiolitis trial Centerwatch nct04502433 poractant alfa status? Clinicaltrials gov poractant alfa bronchiolitis nct?